Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.30.

CGTX has been the subject of a number of analyst reports. HC Wainwright raised their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $1.00 to $1.50 in a report on Thursday, December 19th. Brookline Capital Management raised Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of Cognition Therapeutics in a research note on Thursday, December 19th.

Institutional Investors Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Sigma Planning Corp increased its stake in Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Cognition Therapeutics in the third quarter worth approximately $27,000. SG Americas Securities LLC bought a new stake in shares of Cognition Therapeutics in the fourth quarter worth approximately $26,000. Finally, BIOS Capital Management LP bought a new stake in shares of Cognition Therapeutics in the fourth quarter worth approximately $4,208,000. 43.35% of the stock is owned by hedge funds and other institutional investors.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock opened at $0.58 on Wednesday. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The business has a fifty day moving average price of $0.65 and a 200-day moving average price of $0.61. The firm has a market capitalization of $24.28 million, a P/E ratio of -0.60 and a beta of 0.96.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.